---
reference_id: "PMID:35383534"
title: Clinical use of anti-histone antibodies in idiopathic and drug-induced lupus.
authors:
- Lee AYS
journal: Immunol Med
year: '2022'
doi: 10.1080/25785826.2022.2060168
content_type: abstract_only
---

# Clinical use of anti-histone antibodies in idiopathic and drug-induced lupus.
**Authors:** Lee AYS
**Journal:** Immunol Med (2022)
**DOI:** [10.1080/25785826.2022.2060168](https://doi.org/10.1080/25785826.2022.2060168)

## Content

1. Immunol Med. 2022 Dec;45(4):180-185. doi: 10.1080/25785826.2022.2060168. Epub 
2022 Apr 6.

Clinical use of anti-histone antibodies in idiopathic and drug-induced lupus.

Lee AYS(1)(2)(3).

Author information:
(1)Department of Immunology, Westmead Hospital, Westmead, Australia.
(2)ICPMR, NSW Health Pathology, Westmead, Australia.
(3)Westmead Clinical School, University of Sydney, Westmead, Australia.

Anti-histone antibodies (AHAs) make their appearance in a number of systemic 
autoimmune diseases including systemic lupus erythematosus (SLE) and 
drug-induced lupus erythematosus (DILE). Although being known for over 50â€‰years, 
they are poorly studied and understood. There is emerging evidence for their use 
in predicting clinical features of SLE, diversifying their clinical use. AHAs, 
however, are probably less prevalent in DILE than once thought owing to a move 
away from older DILE drugs to modern biological agents which do not appear to 
elicit AHAs. This review examines the historical studies that have defined AHAs 
and looks at some of the recent work with these autoantibodies.

DOI: 10.1080/25785826.2022.2060168
PMID: 35383534 [Indexed for MEDLINE]